Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPsychiatry/Behavioral Healthmhn TMS Coverage Update: Prior Auth & Limits | Ope…
    Ask Trek AI about this page
    ModifiedmhnPolicy CP.BH.200

    Transcranial Magnetic Stimulation (TMS) for Treatment‑Resistant Major Depression

    Customize your policy alerts

    Sign up for mhn Policy CP.BH.200 alerts

    Get alerted when Policy CP.BH.200 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity, coverage criteria, contraindications, and review pathways for rTMS, dTMS, and iTBS for adults and adolescents with treatment‑resistant major depressive disorder for Centene‑affiliated health plans.

    Policy Summary
    Payermhn
    PolicyTranscranial Magnetic Stimulation (TMS) for Treatment‑Resistant Major Depression
    Policy CodePolicy CP.BH.200
    Change TypeMaterial revisions to authorization limits, documentation, and contraindications (added ketamine/esketamine exclusion)
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization with documentation of two failed antidepressant trials from different classes, comprehensive psychiatric evaluation, and baseline standardized depression rating (e.g., PHQ‑9).
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    Initial authorization session count and additional session limits have been revised multiple times; oversight and review processes were updated and a contraindication for concurrent esketamine/ketamine infusion therapies was added.

    Requirement that oversight of treatment is provided by a licensed psychiatrist (with allowance for state scope of practice exceptions).

    Policy adds coverage language for up to 30 TBS sessions and states that more than 30 TBS sessions lacks sufficient evidence.

    Criteria restructured to require documentation of a standardized depression severity rating scale (e.g., PHQ‑9) pre‑TMS and planned use to monitor response during treatment.

    ≤36authorized sessions per request
    30maximum supported TBS sessions
    2required antidepressant trials
    maintenance TMSnot medically necessary
    31RCTs in evidence review
    90867‑90869referenced CPT codes

    Coverage Criteria for TMS

    Initial Therapy (Adolescents 15–17)

    Covered when ALL of the following are met:

    ALL of the following

    • The member/enrollee has a confirmed diagnosis of major depressive disorder (MDD), severe (single episode or recurrent), per the most recent edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM).
    • The member/enrollee does not have a diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder.
      • ONE of:

        • Failure of two trials of antidepressants from at least two different antidepressant classes administered as an adequate course with a recognized standard therapeutic dose of at least six weeks duration within the last 24 months.
        • Inability to tolerate (documentation of major adverse interactions with medically necessary medications or intolerable side effects) two trials of antidepressants from at least two different antidepressant classes within the last 24 months.
    • The member/enrollee has participated in an adequate trial of evidence-based psychotherapy (such as cognitive behavioral therapy and/or interpersonal therapy) during the current episode of illness, without significant improvement. Note: This therapy should overlap with the antidepressant trials.
    • The member/enrollee has failed a trial of electroconvulsive therapy (ECT); or its use is contraindicated or there is documentation by a psychiatrist indicating why TMS is clinically preferable.
    • The requested treatment is administered using the NeuroStar® TMS Therapy System, as an adjunct for the treatment of MDD, in accordance with the specific FDA-labeled indication.
    • A comprehensive psychiatric evaluation to determine the necessity for TMS has been completed by a qualified licensed provider (e.g., psychiatrist MD/DO/MBBS or psychiatric nurse practitioner).
    • Direct supervision of treatment is provided by a licensed psychiatrist, trained in TMS therapy, except where state scope of practice acts allow for other provider types to supervise.
    • Request is for up to 36 sessions (recommended schedule: five days a week for six weeks, with an optional six sessions for tapering).
      • NONE of the following:

        • Presence of conductive or ferromagnetic or other magnetic-sensitive metals implanted or embedded in head or neck within 30 cm of TMS coil placement other than dental fillings (e.g., cochlear implant; implanted electrodes/stimulators; aneurysm clips or coils; stents; bullet fragments; metallic dyes in tattoos).
        • Vagus nerve stimulator leads in the carotid sheath.
        • Less than three months of substantiated remission from substance use disorder.
        • Concomitant esketamine intranasal, ketamine infusion or other infusion therapies.
        • Not experiencing acute active suicidal ideation with intent.
    • Documentation of rTMS/iTBS/dTMS protocol used.
    • Planned use of an adolescent, evidence-based, standardized depression rating scale (including severity), documenting the score prior to treatment, and monitored throughout the course of treatment.
    • The member/enrollee is referred for TMS treatment by the provider treating the member/enrollee's MDD.

    Not Medically Necessary / Experimental

    Not covered / Experimental when ANY of the following apply:

    paragraphs([])

    Coding and Procedural References

    FDA-cleared devices (examples)mixed
    NeuroStarNeuroStar ® Advanced TMS Therapy System
    Apollo TMS Therapy SystemApollo TMS Therapy System
    BrainsWay Deep TMSBrainsWay Deep TMS
    Horizon TMS Therapy SystemHorizon TMS Therapy System
    MagVita TMS Therapy with MagPro R20MagVita TMS Therapy with MagPro R20
    MagVita TMS Therapy System w/Theta Burst StimulationMagVita TMS Therapy System w/Theta Burst Stimulation
    Neurosoft TMA (Cloud TMS)Neurosoft TMA (Cloud TMS)
    Nexstim Brain TherapyNexstim Brain Therapy
    Magstim Horizon 3.0 TMS Therapy System RangeMagstim Horizon 3.0 TMS Therapy System Range
    Referenced CPT codesCPT
    90867Therapeutic repetitive transcranial magnetic stimulation (tms) treatment; initial, including cortical mapping, motor threshold determination, delivery, and management.
    90868Therapeutic repetitive transcranial magnetic stimulation (tms) treatment; subsequent delivery and management, per session.
    90869Therapeutic repetitive transcranial magnetic stimulation (tms) treatment; subsequent motor threshold re-determination with delivery and management.
    97014Application of a modality to 1 or more areas; electrical stimulation (unattended).
    97032Application of a modality to 1 or more areas; electrical stimulation (manual), each 15 minutes.
    Referenced CPT/Category III codesCPT
    0889T-0892TCategory III codes referenced in external Medical Code Brief (Hayes) describing delivery and reporting elements for TMS procedures.
    Antidepressant trial adequacy — adults
    Required antidepressant trialsAt least two trials of antidepressants from at least two different classes given at recognized therapeutic doses for ≥6 weeks within the last 24 months (or documented inability to tolerate four trials from ≥2 classes).
    Documentation standardFailure or intolerance must be documented (PHQ-9 ≥15 indicates moderately severe to severe depression).
    Time windowAdequate trials must be within the last 24 months when applicable.
    Session limit — standard course and tapering guidance
    Standard request limitRequest for up to 36 sessions per course; recommended schedule five days/week for six weeks.

    Provider Actions, Documentation & Authorization

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for initial and retreatment TMS requests. Initial requests for adults (≥18) may be authorized for up to 36 sessions (recommended schedule five days/week for six weeks with optional six taper sessions). Requests for additional or retreatment sessions are reviewed case-by-case by medical director; limits on Theta Burst Stimulation (TBS) apply (more than 30 TBS sessions may be denied). Maintenance TMS (ongoing/recurring maintenance courses) is considered not medically necessary and will be denied.

    • Initial prior authorization required; initial request reviewed for up to 36 sessions (note: recommended 5 days/week × 6 weeks; optional 6 taper sessions)
    • Retreatment/additional sessions reviewed case-by-case by medical director
    • Requests >30 TBS sessions may be denied; maintenance TMS is not medically necessary
    Documentation Required

    Required Documentation for Prior Authorization

    Background and Evidence Summary

    Transcranial Magnetic Stimulation (TMS) refers to non‑invasive neuromodulation techniques that use pulsed magnetic fields to induce focal cortical currents. Common modalities include repetitive TMS (rTMS), which typically delivers trains of pulses (often ≥10 Hz) to surface cortical targets; deep TMS (dTMS), which uses specialized coils (e.g., H‑coil) to stimulate deeper brain regions; and intermittent Theta Burst Stimulation (iTBS/TBS), a patterned, high‑frequency burst protocol that delivers short bursts of pulses (e.g., 50 Hz bursts producing an overall 5 Hz pattern).

    Mechanistically, these modalities aim to modulate cortical excitability and downstream networks implicated in mood regulation. The policy requires use of FDA‑cleared devices and documentation of the specific protocol used, and it specifies monitoring with standardized depression rating scales before and during treatment to assess clinical response.

    A pediatric randomized sham‑controlled trial (Croarkin et al.) enrolling adolescents found no difference between active 10‑Hz TMS and sham on the primary HAM‑D outcome after 30 treatments, and remission/response rates were similar between groups. The policy cites this trial and a Hayes coding brief which concluded that current evidence for adolescent iTBS and MRI‑guided TBS is weak, informing the policy’s conservative stance toward routine adolescent coverage.

    Consequently, adolescent requests (ages 15–17) are subject to case‑by‑case medical director review, and evidence limitations should be documented in authorization requests.

    The policy acknowledges inclusion of accelerated iTBS protocols and fcMRI‑guided targeting (SAINT/SNT) in the evidence discussion but treats these approaches as investigational. The document references the small SAINT series (50 iTBS sessions delivered as 10 daily sessions over 5 days with high remission rates in n=21) and notes that while tolerated, randomized evidence is limited and insufficient to alter coverage determinations.

    Hayes reviews and the policy’s revision notes are cited to show that MRI‑guided, accelerated high‑dose iTBS and fcMRI‑targeting techniques remain unsupported for routine coverage pending larger, confirmatory trials.

    Defined Modalities and Definitions

    TMS (rTMS, dTMS, iTBS)

    Treatment must meet the following modality-level requirements:

    TMS modality criteria: Treatment must be delivered using an FDA‑cleared device and in accordance with labeled indications; documentation of the specific protocol used (rTMS, dTMS, or iTBS) is required; providers must monitor response using a standardized depression severity rating scale; contraindications must be absent.all conditions required

    For adolescents, NeuroStar® is specified per FDA-labeled indication.

    TMS (rTMS, dTMS, iTBS, accelerated iTBS)

    Modalities included and additional protocols described:

    Modalities described: Includes conventional rTMS, deep TMS (dTMS), intermittent theta burst stimulation (iTBS)/theta burst stimulation (TBS), and accelerated high‑dose iTBS protocols (e.g., SAINT/SNT).

    Evidence summaries and examples of accelerated protocols are referenced in background and revision notes.

    Visit and Session Limits

    rTMS/iTBS/dTMS sessions — standard request value
    Standard request valueStandard request/authorization value referenced in policy: up to 36 rTMS/iTBS/dTMS sessions per course.
    Recommended scheduleRecommended schedule specified as five days per week for six weeks.
    Optional taperPolicy notes an optional six taper sessions may be included in some guidance.
    TMS sessions — historical initial counts and additional session limits
    Historical initial countsInitial authorization session counts have historically been set at either 20 or 30 sessions in different revisions of the policy.
    Additional session limits (historical)Additional/booster session limits were revised across versions (examples include 20 → 10 → 6 additional sessions in various revisions).

    Level of Care and Setting

    Policy Revision History

    02/21policy_revision

    Changed medical necessity statements to require review by a medical director; initial sessions revised from 30 to 20 in this revision and minor edits to clarify review process.

    02/22policy_revision

    Revision noted in annual review adjusting initial sessions (referenced as changed from 30 to 20) with approval recorded 02/22.

    05/20policy_revision
    Policy Summary
    Payermhn
    PolicyTranscranial Magnetic Stimulation (TMS) for Treatment‑Resistant Major Depression
    Policy CodePolicy CP.BH.200
    Change TypeMaterial revisions to authorization limits, documentation, and contraindications (added ketamine/esketamine exclusion)
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization with documentation of two failed antidepressant trials from different classes, comprehensive psychiatric evaluation, and baseline standardized depression rating (e.g., PHQ‑9).
    SourceLink
    On This Page
    Coverage Criteria for TMSCoding and Procedural ReferencesProvider Actions, Documentation & AuthorizationBackground and Evidence SummaryDefined Modalities and DefinitionsVisit and Session LimitsLevel of Care and SettingPolicy Revision History
    Optional taper
    An optional six taper sessions may be requested (described as tapering over ~3 weeks in some revisions).
    Typical frequencyRecommended frequency: daily (5 days per week) for approximately 6 weeks.
    Authorization noteInitial and retreatment requests require prior authorization; additional/taper sessions reviewed case-by-case.
    SAINT iTBS dosing example
    SAINT (accelerated iTBS) example50 iTBS sessions (1,800 pulses per session) delivered as 10 daily sessions over 5 consecutive days with ~50‑minute intersession intervals at 90% resting motor threshold (depth‑adjusted).
    Sample size/resultIn the cited SAINT pilot, 19 of 21 participants (90.5%) met remission (MADRS <11).
    Targeting and intensityProtocol used fcMRI‑guided targeting and depth‑adjusted motor threshold (90%).
    Maximum supported TBS sessions
    Policy maximum for TBSPolicy states there is insufficient evidence to support more than 30 sessions of Theta Burst Stimulation (TBS); supported maximum stated as 30 sessions.
    Coverage statement contextPolicy added explicit statement limiting TBS to up to a total of 30 sessions in criteria revisions.
    Denial riskRequests for >30 TBS sessions may be denied due to insufficient evidence.

    The prior authorization request must include comprehensive documentation to support medical necessity: a psychiatric evaluation, treatment history, standardized outcome measures, and the specific TMS protocol. Insufficient documentation of required prior trials, psychotherapy, or ECT trial/contraindication may result in denial.

    • Comprehensive psychiatric evaluation by qualified licensed provider (psychiatrist MD/DO/MBBS or psychiatric nurse practitioner)
    • Documentation of the rTMS, iTBS, or dTMS protocol to be used
    • Planned use of an evidence‑based standardized depression rating scale (e.g., PHQ‑9) with pre‑treatment score documented and ongoing monitoring during treatment
    • Clear documentation if ECT was tried and failed, contraindicated, or why TMS is clinically preferable
    Step Therapy

    Required Prior Trials, Step Therapy & Medication/Augmentation History

    Prior to authorization, the member/enrollee must have adequate prior trials and step therapy as follows. Documentation must show failure or intolerance as specified, and a history of medication augmentation attempts when applicable.

    • Failure of at least two antidepressant trials from two different classes administered at adequate dose and duration (≥6 weeks) within the last 24 months OR documented inability to tolerate antidepressant trials as specified in policy (e.g., intolerable side effects)
    • Documentation of participation in an adequate trial of evidence‑based psychotherapy (e.g., CBT or interpersonal therapy) during the current episode, overlapping with antidepressant trials, without significant improvement
    • When applicable, documentation of at least two recognized augmentation treatments attempted (for treatment‑resistant cases) such as lithium, thyroid hormone, second‑generation antipsychotic augmentation, or dual antidepressant approaches
    • Medication/augmentation history and prior psychopharmacologic trials must be detailed in the request; insufficient history may result in denial
    Note

    Evaluation, Referral & Clinical Oversight

    Clinical oversight and referral requirements: a comprehensive psychiatric evaluation must be completed and the patient referred for TMS by the provider treating the MDD. Direct supervision of TMS treatment must be provided by a licensed psychiatrist trained in TMS (except where state scope allows otherwise). Medical director review is used for adolescent requests and for authorization of additional/retreatment sessions.

    • Referral for TMS by the provider treating the member's MDD
    • Comprehensive psychiatric evaluation by a qualified licensed provider completed prior to treatment
    • Direct supervision by a licensed psychiatrist trained in TMS, unless state scope permits other supervisors
    • Medical director case‑by‑case review for adolescents (15–17) and for retreatment/additional sessions
    Documentation Required

    Protocol & Outcome Measurement Requirements

    Protocol and outcome measurement expectations: the TMS provider must document the specific protocol (rTMS, iTBS, or dTMS), device used (FDA‑cleared device), stimulation parameters, and planned outcome measurement using standardized depression rating scales. Scores must be recorded prior to initiation and monitored throughout treatment to support continued authorization.

    • Documentation of TMS protocol (rTMS, iTBS, or dTMS) and device (FDA‑cleared) with stimulation parameters
    • Planned use of an evidence‑based standardized depression rating scale (e.g., PHQ‑9, PHQ‑A for teens, MADRS) with pre‑TMS score documented
    • Ongoing measurement of standardized rating scale scores during course of treatment to document response or lack of response
    Note

    Evidence Supporting SUD and Comorbidity Exclusions

    Evidence note: A randomized clinical trial by Yesavage et al. (2018) in US veterans was used to support exclusions related to treatment in the presence of ongoing substance use disorder, PTSD, and certain comorbidities. Include relevant comorbidity and SUD remission documentation as required.

    • Yesavage JA et al., Effect of Repetitive Transcranial Magnetic Stimulation on Treatment‑Resistant Major Depression in US Veterans (JAMA Psychiatry, 2018) supports exclusion considerations for active SUD, PTSD, and comorbidity
    • Policy requires documentation of at least three months of substantiated remission from substance use disorder prior to treatment

    TMS (rTMS, iTBS/TBS, dTMS)

    Policy allowance and modality-specific limits:

    rTMS/iTBS/dTMS inclusion: Policy includes rTMS, intermittent TBS (iTBS/TBS), and deep TMS (dTMS) as covered modalities for adults when medical necessity criteria are met; documentation of the specific protocol must be provided; policy states up to 30 total TBS sessions are supported and that more than 30 TBS sessions lacks sufficient evidence.

    MRI‑guided theta burst and some MRI‑guided accelerated protocols are considered experimental/investigational.

    rTMS — definition
    DefinitionrTMS: repetitive transcranial magnetic stimulation delivering trains of magnetic pulses (often ≥10 Hz) targeting the dorsolateral prefrontal cortex for MDD treatment.
    MechanismDelivers multiple single‑pulse stimuli in rapid series at specified frequency, intensity, and duration.
    Clinical useMost widespread form of TMS used in clinical applications for depression.
    dTMS — definition
    DefinitiondTMS (deep TMS): uses specialized H‑coils to stimulate deeper and wider cortical regions (approximately 4 cm depth) compared with surface coils.
    Coil typeH‑coil design provides deeper and wider distribution and also stimulates surface cortical structures.
    Clinical noteIncluded in policy as a covered form of TMS for adults when criteria are met; evidence suggests comparable efficacy/acceptability to surface TMS in some trials.
    iTBS — definition
    DefinitioniTBS (intermittent Theta Burst Stimulation): a patterned form of rTMS delivering short bursts of 3–5 pulses at high frequency (50 Hz) with interburst intervals producing an overall 5 Hz stimulation frequency.
    Pulse patternShort bursts at 50 Hz arranged with interburst intervals to yield an effective 5 Hz repetition rate.
    Relation to rTMSiTBS is a form of rTMS that uses theta‑burst patterned stimulation to reduce session duration and total pulses while aiming for therapeutic effect.
    TBS / Theta Burst Stimulation — definition and policy limits
    DefinitionTBS (Theta Burst Stimulation): a patterned form of TMS using bursts of high‑frequency pulses (theta burst paradigms such as iTBS).
    Policy limitPolicy allows up to 30 sessions of TBS and explicitly states there is insufficient evidence to support more than 30 sessions.
    Experimental noteMRI‑guided theta burst (e.g., SAINT) is described in background but MRI‑guided theta burst is considered experimental/investigational in policy statements.
    dTMS included as a form of TMS for adults ≥18 years
    Inclusion in adult criteriaDeep TMS (dTMS) is included as a form of TMS for adults ≥18 years in the policy criteria when other coverage requirements are met.
    Documentation requirementPolicy requires documentation of the specific TMS protocol (rTMS, iTBS/TBS, or dTMS) used.
    Device requirementTreatment must be administered using an FDA‑cleared device per labeled indications.
    Review processInitial counts and requests for additional sessions have been subject to case‑by‑case medical director review per revision notes.
    TMS sessions — TBS limit and up to 36 including optional tapering
    TBS and total sessions guidancePolicy references up to 30 sessions specifically for TBS and up to 36 total sessions including optional tapering in other text.
    Taper authorization exampleFor patients meeting response criteria after 30 sessions, authorization of up to 6 taper sessions over ~3 weeks has been described in revisions.
    Policy emphasisWhile up to 36 sessions are referenced for standard courses, the policy emphasizes a supported maximum of 30 TBS sessions due to evidence limitations for >30.

    Policy/Criteria updated to clarify Section I refers to initial approval; oversight language updated to state oversight provided by a licensed psychiatrist; added that initial requests can be reviewed for up to 20 TMS sessions and added Section II for authorization of additional sessions.

    08/22policy_revisionLatest

    Initial number of sessions changed from 20 to 30 for authorizations reviewed case-by-case; additional sessions limit changed from 10 to 6; added statement allowing requests for six tapered final sessions over 3 weeks and other editorial housekeeping (header/date label changes, 'member' → 'member/enrollee').